155The Court has held, having specific regard to the exclusive nature of the criteria of safety, efficacy and quality laid down in the context of the EU system for the harmonisation of the grant and management of MAs for medicinal products, that the assessment of the proportionality of a measure suspending or withdrawing an MA was to be guided by those criteria alone. It follows that the relevant interests in the context of the review of proportionality are the same as those related to the protection of public health, taken into consideration in the application of the relevant legislation (see, to that effect, judgment of 3 March 2010, Artegodan v Commission, T‑429/05, EU:T:2010:60, paragraph 128).
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.